ライフサイエンスコーパス: pulmonary arterial hypertension

1 0.03 mg/kg, in the rat moncrotaline model of pulmonary arterial hypertension.

2 oth muscle cell survival patterns to promote pulmonary arterial hypertension.

3 e progression-free survival of patients with pulmonary arterial hypertension.

4 cular disorders, including heart failure and pulmonary arterial hypertension.

5 a is a critical regulator of hypoxia-induced pulmonary arterial hypertension.

6 s, including cancer, kidney nephropathy, and pulmonary arterial hypertension.

7 of a new treatment option for patients with pulmonary arterial hypertension.

8 pathology, compared with other patients with pulmonary arterial hypertension.

9 FNA1 may underlie vulnerability to injury in pulmonary arterial hypertension.

10 ole cohort, and 89 and 85% for patients with pulmonary arterial hypertension.

11 ssels and plexiform lesions of patients with pulmonary arterial hypertension.

12 related with skin and lung fibrosis and with pulmonary arterial hypertension.

13 nction (PED) has been described in HF and in pulmonary arterial hypertension.

14 Cpc-PH bears similarities to pulmonary arterial hypertension.

15 splayed favorable survival for children with pulmonary arterial hypertension.

16 lls (HPAECs) to promote vascular fibrosis in pulmonary arterial hypertension.

17 rminant of functional state and prognosis in pulmonary arterial hypertension.

18 immune processes underlie the development of pulmonary arterial hypertension.

19 of complications, such as lung fibrosis and pulmonary arterial hypertension.

20 quality of life in patients with idiopathic pulmonary arterial hypertension.

21 may contribute to the vascular pathology of pulmonary arterial hypertension.

22 these models and in lungs from patients with pulmonary arterial hypertension.

23 ing demographics of patients with idiopathic pulmonary arterial hypertension.

24 d compound was markedly reduced in rats with pulmonary arterial hypertension.

25 condary efficacy end points in patients with pulmonary arterial hypertension.

26 el gene, KCNK3, with familial and idiopathic pulmonary arterial hypertension.

27 roducible prognostic marker in patients with pulmonary arterial hypertension.

28 or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension.

29 he ER-mitochondrial unit and prevent/reverse pulmonary arterial hypertension.

30 tan is beneficial for long-term treatment of pulmonary arterial hypertension.

31 monotherapy in patients with newly diagnosed pulmonary arterial hypertension.

32 as heart failure, arterial hypertension, and pulmonary arterial hypertension.

33 e, chronic obstructive pulmonary disease, or pulmonary arterial hypertension.

34 ents known to be effective in other forms of pulmonary arterial hypertension.

35 ental to well-validated prognostic scores in pulmonary arterial hypertension.

36 nd 3DTTE) were performed in 22 patients with pulmonary arterial hypertension (54+/-13 years of age) t

37 ts who died (28/37) had idiopathic/heritable pulmonary arterial hypertension (76% versus 33% overall)

38 cts 63%, pulmonary alveolar proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts

39 ific medications enrolled in the Imatinib in Pulmonary Arterial Hypertension, a Randomized Efficacy S

40 Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy

41 e Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial.

42 int prevalence of 0.7 and 4.4 for idiopathic pulmonary arterial hypertension and 2.2 and 15.6 for pul

43 lmonary adventitia of humans with idiopathic pulmonary arterial hypertension and animals with PH and

44 mia is prevalent in patients with idiopathic pulmonary arterial hypertension and associated with redu

45 ortant role in various pathologies including pulmonary arterial hypertension and cardiomyopathy.

46 were associated with poor survival for both pulmonary arterial hypertension and chronic thromboembol

47 The hyperproliferative ECs of human pulmonary arterial hypertension and glioblastoma multifo

48 tor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under clin

49 as downregulated in patients with idiopathic pulmonary arterial hypertension and in rats treated with

50 othelial cells from patients with idiopathic pulmonary arterial hypertension and in the pulmonary vas

51 nsibility is reduced in patients with HF and pulmonary arterial hypertension and is closely related t

52 rtant features leading to RV lipotoxicity in pulmonary arterial hypertension and may point to novel a

53 cating a role for this versatile cytokine in pulmonary arterial hypertension and neoplastic diseases.

54 ts who were receiving no other treatment for pulmonary arterial hypertension and patients who were re

55 ung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH.

56 ole of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic acti

57 long-term use of riociguat in patients with pulmonary arterial hypertension, and emphasise the progn

58 ecapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with po

59 terial hypertension, rats with Sugen/hypoxia-pulmonary arterial hypertension, and mice exposed to chr

60 scular necrosis, severe splenic dysfunction, pulmonary arterial hypertension, and sepsis, which may r

61 n focus on World Health Organization group 1 pulmonary arterial hypertension, and the efficacy of man

62 Placebo-controlled trials for pulmonary arterial hypertension are no longer acceptable

63 rtension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established

64 ways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including

65 lafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.

66 boembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.

67 Familial cases of pulmonary arterial hypertension are usually characterize

68 es, comprising interstitial lung disease and pulmonary arterial hypertension, are the leading causes

69 n transplantation candidates with idiopathic pulmonary arterial hypertension, as is being listed at a

70 n human clinical trials for the treatment of pulmonary arterial hypertension, as well as other cardio

71 Pulmonary arterial hypertension associated with congenit

72 specially in younger children and those with pulmonary arterial hypertension associated with congenit

73 on profiles in the sera of the patients with pulmonary arterial hypertension associated with congenit

74 othelial cells from patients with idiopathic pulmonary arterial hypertension attenuated the abnormal

75 gnaling is implicated in the pathogenesis of pulmonary arterial hypertension, based in part on the ab

76 t common forms of pulmonary hypertension are pulmonary arterial hypertension, chronic thromboembolic

77 from patients with idiopathic and heritable pulmonary arterial hypertension compared with control su

78 the established prognostic risk equation for pulmonary arterial hypertension derived from the REVEAL

79 e disease, such as scleroderma renal crisis, pulmonary arterial hypertension, digital ulceration, and

80 site of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or

81 ing costs for the planning of a hypothetical pulmonary arterial hypertension drug trial using imaging

82 ment variability, CMR is more cost saving in pulmonary arterial hypertension drug trials than echocar

83 Studies evaluating the effect of pulmonary arterial hypertension drugs currently not appr

84 Idiopathic and heritable pulmonary arterial hypertension form a rare but molecula

85 In familial pulmonary arterial hypertension (FPAH), the autosomal do

86 rolled patients with idiopathic or heritable pulmonary arterial hypertension from London (UK; cohorts

87 PV distensibility was lowest in the pulmonary arterial hypertension group (0.40+/-0.24% per

88 The treatment of pulmonary arterial hypertension has advanced substantial

89 s in the pulmonary arteries of patients with pulmonary arterial hypertension has been described for d

90 Current therapies for pulmonary arterial hypertension have been adopted on the

91 Hereditary pulmonary arterial hypertension (HPAH) is a rare, fatal

92 I receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH).

93 sessed sildenafil in pediatric patients with pulmonary arterial hypertension; improved hemodynamics a

94 aired samples from 43 incident patients with pulmonary arterial hypertension in cohort 3 (p=0.0133).

95 in 93 patients with idiopathic or heritable pulmonary arterial hypertension in cohort 4, with 4.4 ye

96 pulmonary disease patients and less cases of pulmonary arterial hypertension in NS group.

97 POPH is characterized by development of pulmonary arterial hypertension in the setting of portal

98 morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven stu

99 was incremental to risk prediction scores in pulmonary arterial hypertension, including the Registry

100 is a strong prognostic marker in idiopathic pulmonary arterial hypertension, independent of invasive

101 In treatment-naive patients with pulmonary arterial hypertension, initial combination the

102 Idiopathic pulmonary arterial hypertension (IPAH) is a cardiopulmon

103 Idiopathic pulmonary arterial hypertension (IPAH) is a life-threate

104 Idiopathic pulmonary arterial hypertension (IPAH) is usually withou

105 red hyaluronan (HA) metabolism in idiopathic pulmonary arterial hypertension (IPAH) lung tissue and c

106 Idiopathic pulmonary arterial hypertension (IPAH) results in increa

107 anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH).

108 een recommended for patients with idiopathic pulmonary arterial hypertension (IPAH).

109 , have been used for treatment of idiopathic pulmonary arterial hypertension (IPAH).

110 fied as pre-capillary (as seen in idiopathic pulmonary arterial hypertension [IPAH]) or post-capillar

111 Pulmonary arterial hypertension is a chronic disease ass

112 Pulmonary arterial hypertension is a chronic lung diseas

113 Pulmonary arterial hypertension is a devastating disease

114 Pulmonary arterial hypertension is a progressive disorde

115 Pulmonary arterial hypertension is characterized by endo

116 Pulmonary arterial hypertension is characterized by endo

117 RATIONALE: Idiopathic or heritable pulmonary arterial hypertension is characterized by loss

118 Pulmonary arterial hypertension is characterized by vasc

119 The incidence of pulmonary arterial hypertension is greater in women, sug

120 entifying predictors of long-term outcome in pulmonary arterial hypertension is important to assess d

121 ntation outcomes in patients with idiopathic pulmonary arterial hypertension is poorly described.

122 ular (RV) pressure overload in patients with pulmonary arterial hypertension is unknown.

123 iver of (chronic) human disorders, including pulmonary arterial hypertension, kidney disease, and ath

124 ular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a b

125 atients were classified as follows: group I, pulmonary arterial hypertension (n = 142; 61%); group II

126 The majority had idiopathic pulmonary arterial hypertension (n=30); the remaining pa

127 ve study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic th

128 osis (OR, 2.5; 95% CI, 1.1-5.6; P = 0.03) or pulmonary arterial hypertension (OR, 3.5; 95% CI, 1.6-7.

129 ality included an etiologic group other than pulmonary arterial hypertension (P < 0.001), age at diag

130 Idiopathic pulmonary arterial hypertension (PAH [IPAH]) is an insid

131 l efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described.

132 hanisms of right ventricular (RV) failure in pulmonary arterial hypertension (PAH) are poorly underst

133 ast, limited data support anticoagulation in pulmonary arterial hypertension (PAH) associated with sy

134 artery in control subjects and patients with pulmonary arterial hypertension (PAH) at rest.

135 onsistently been associated with survival in pulmonary arterial hypertension (PAH) at the time of dia

136 Pulmonary arterial hypertension (PAH) contributes to dis

137 enetic basis for heritable predisposition to pulmonary arterial hypertension (PAH) has altered the cl

138 of imatinib mesylate to reverse established pulmonary arterial hypertension (PAH) has been attribute

139 of cardiovascular risk, however, its role in pulmonary arterial hypertension (PAH) has not been deter

140 s the pulmonary phenotype and BPD-associated pulmonary arterial hypertension (PAH) in BPD mouse model

141 lls (PAECs) from patients who had idiopathic pulmonary arterial hypertension (PAH) in comparison with

142 ons are hallmarks of the pathology of severe pulmonary arterial hypertension (PAH) in patients.

143 rvival and treatment strategies in pediatric pulmonary arterial hypertension (PAH) in the current era

144 r system, to seek evidence for alteration in pulmonary arterial hypertension (PAH) in which apelin si

145 The vascular remodeling responsible for pulmonary arterial hypertension (PAH) involves predomina

146 Pulmonary arterial hypertension (PAH) is a cardiopulmona

147 Pulmonary arterial hypertension (PAH) is a chronic and p

148 Pulmonary arterial hypertension (PAH) is a fatal conditi

149 Pulmonary arterial hypertension (PAH) is a fatal disease

150 Pulmonary arterial hypertension (PAH) is a heterogeneous

151 Pulmonary arterial hypertension (PAH) is a lethal diseas

152 Pulmonary arterial hypertension (PAH) is a life-threaten

153 Heterogeneity in response to treatment of pulmonary arterial hypertension (PAH) is a major challen

154 Pulmonary arterial hypertension (PAH) is a medically inc

155 Pulmonary arterial hypertension (PAH) is a progressive a

156 Pulmonary arterial hypertension (PAH) is a progressive d

157 Pulmonary arterial hypertension (PAH) is a progressive d

158 Pulmonary arterial hypertension (PAH) is a progressive l

159 Pulmonary arterial hypertension (PAH) is a progressive,

160 Pulmonary arterial hypertension (PAH) is a proliferative

161 Pulmonary arterial hypertension (PAH) is a rare cardiopu

162 Pulmonary arterial hypertension (PAH) is a rare disease

163 Pulmonary arterial hypertension (PAH) is a serious lung

164 Pulmonary arterial hypertension (PAH) is a vascular remo

165 Pulmonary arterial hypertension (PAH) is a vasculopathy

166 RATIONALE: Pulmonary arterial hypertension (PAH) is an obstructive

167 Pulmonary arterial hypertension (PAH) is an obstructive

168 Pulmonary arterial hypertension (PAH) is an often fatal

169 Pulmonary arterial hypertension (PAH) is an uncommon dis

170 Pulmonary arterial hypertension (PAH) is associated with

171 Pulmonary arterial hypertension (PAH) is characterized b

172 Importance: Pulmonary arterial hypertension (PAH) is characterized b

173 Pulmonary arterial hypertension (PAH) is characterized b

174 LV dysfunction in pulmonary arterial hypertension (PAH) is characterized b

175 , familial, or secondary to another disease, pulmonary arterial hypertension (PAH) is characterized b

176 Pulmonary arterial hypertension (PAH) is characterized b

177 Pulmonary arterial hypertension (PAH) is characterized b

178 Pulmonary arterial hypertension (PAH) is characterized b

179 Pulmonary arterial hypertension (PAH) is characterized b

180 Pulmonary arterial hypertension (PAH) is characterized b

181 Survival in patients with pulmonary arterial hypertension (PAH) is closely related

182 Pulmonary arterial hypertension (PAH) is commonly associ

183 Pulmonary arterial hypertension (PAH) is differentiated

184 nce-based treatment guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lac

185 severity and predicting outcome in pediatric pulmonary arterial hypertension (PAH) is insufficiently

186 alterations of the pulmonary vasculature in pulmonary arterial hypertension (PAH) is primarily provi

187 mitation in the pharmacological treatment of pulmonary arterial hypertension (PAH) is the lack of pul

188 Although WHO Group I pulmonary arterial hypertension (PAH) is the most common

189 eraction contributes to small vessel loss in pulmonary arterial hypertension (PAH) is unclear.

190 solated right ventricular failure because of pulmonary arterial hypertension (PAH) is unclear.

191 , but its efficacy in treating patients with pulmonary arterial hypertension (PAH) is unknown.

192 Pulmonary arterial hypertension (PAH) remains a concern

193 lure, but whether it would be beneficial for pulmonary arterial hypertension (PAH) remains to be expl

194 pies for pulmonary vascular diseases such as pulmonary arterial hypertension (PAH) remains unknown.

195 Current pharmacological interventions for pulmonary arterial hypertension (PAH) require continuous

196 n linked to occlusive vascular remodeling in pulmonary arterial hypertension (PAH) that is hereditary

197 Murine models of pulmonary arterial hypertension (PAH) that recapitulate

198 Incident development of pulmonary arterial hypertension (PAH) was not benign, wi

199 The etiology of schistosomiasis-associated pulmonary arterial hypertension (PAH), a major cause of

200 In pulmonary arterial hypertension (PAH), acute vasodilator

201 function (LVSD), diastolic dysfunction (DD), pulmonary arterial hypertension (PAH), and increased lef

202 diastolic dysfunction influences outcomes in pulmonary arterial hypertension (PAH), but echocardiogra

203 the role of female sex and estradiol (E2) in pulmonary arterial hypertension (PAH), but it is not kno

204 mutations in the CAV1 gene in patients with pulmonary arterial hypertension (PAH), but the mechanism

205 e linked to progressive small vessel loss in pulmonary arterial hypertension (PAH), but the molecular

206 ng evidence that microRNAs are implicated in pulmonary arterial hypertension (PAH), but underlying me

207 lecular abnormalities have been described in pulmonary arterial hypertension (PAH), complicating the

208 rm lesions (PLs), the hallmark of plexogenic pulmonary arterial hypertension (PAH), contain phenotypi

209 levels of aldosterone activate Akt, and, in pulmonary arterial hypertension (PAH), correlate with pu

210 plays a central role in the pathogenesis of pulmonary arterial hypertension (PAH), promoting vasocon

211 surements in the management of children with pulmonary arterial hypertension (PAH), we assessed growt

212 Importance: Recent trends and outcomes of pulmonary arterial hypertension (PAH)-related hospitaliz

213 proliferation, leading to the development of pulmonary arterial hypertension (PAH).

214 sure is an established prognostic measure in pulmonary arterial hypertension (PAH).

215 cell (PASMC) phenotype and are implicated in pulmonary arterial hypertension (PAH).

216 long-term therapeutics for the treatment of pulmonary arterial hypertension (PAH).

217 on are considered two primary instigators of pulmonary arterial hypertension (PAH).

218 nt factor of both morbidity and mortality in pulmonary arterial hypertension (PAH).

219 n the endothelium as an initiating factor in pulmonary arterial hypertension (PAH).

220 reasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH).

221 Schistosomiasis is a major cause of pulmonary arterial hypertension (PAH).

222 pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH).

223 in the evaluation and care of patients with pulmonary arterial hypertension (PAH).

224 be extended to patients with other forms of pulmonary arterial hypertension (PAH).

225 asing of a link between interferon (IFN) and pulmonary arterial hypertension (PAH).

226 atients and defining treatment strategies in pulmonary arterial hypertension (PAH).

227 wined with the initiation and progression of pulmonary arterial hypertension (PAH).

228 duct, S1P, play a role in the development of pulmonary arterial hypertension (PAH).

229 a surrogate end point for clinical events in pulmonary arterial hypertension (PAH).

230 uld be efficacious in treating patients with pulmonary arterial hypertension (PAH).

231 n important factor in the pathophysiology of pulmonary arterial hypertension (PAH).

232 in the field of hereditary predisposition to pulmonary arterial hypertension (PAH).

233 f various cardiovascular diseases, including pulmonary arterial hypertension (PAH).

234 ding death are understudied in patients with pulmonary arterial hypertension (PAH).

235 ated with negative outcomes in children with pulmonary arterial hypertension (PAH).

236 s been identified in a family with heritable pulmonary arterial hypertension (PAH).

237 s been identified in a family with heritable pulmonary arterial hypertension (PAH).

238 racteristic hallmarks in the pathogenesis of pulmonary arterial hypertension (PAH).

239 eceptor type 2 mutation-associated heritable pulmonary arterial hypertension (PAH).

240 ed in some patients suffering from heritable pulmonary arterial hypertension (PAH).

241 4 inactivation confers a survival benefit in pulmonary arterial hypertension (PAH).

242 mponents of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH).

243 onal capacity and prognosis in patients with pulmonary arterial hypertension (PAH).

244 r if Cpc-PH shares molecular similarities to pulmonary arterial hypertension (PAH).

245 I (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH).

246 Females are predisposed to pulmonary arterial hypertension (PAH); evidence suggests

247 Healthy controls (n=10) and children with pulmonary arterial hypertension (PAH; n=10) and repaired

248 cently shown to be increased in the lungs of pulmonary arterial hypertension patients, and in respons

249 In lung from pulmonary arterial hypertension patients, PW1-expressing

250 ns commonly asked by patients diagnosed with pulmonary arterial hypertension pertaining to the diseas

251 Pulmonary arterial hypertension (PH), whether idiopathic

252 ypoxia-induced PH and humans with idiopathic pulmonary arterial hypertension (PH-Fibs) displayed aero

253 Patients with pulmonary arterial hypertension, rats with Sugen/hypoxia

254 ters and long-term outcomes in patients with pulmonary arterial hypertension receiving riociguat in t

255 he overall prognosis of patients with severe pulmonary arterial hypertension remains poor.

256 y arterial hypertension and 2.2 and 15.6 for pulmonary arterial hypertension, respectively, associate

257 The pathogenic mechanisms underlying pulmonary arterial hypertension resulting from schistoso

258 Patients with hemodynamics of pulmonary arterial hypertension should be referred to sp

259 Patients requiring additional pulmonary arterial hypertension-specific therapy discont

260 Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a rare dise

261 ent-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension (STARTS-1) study assesse

262 Idiopathic pulmonary arterial hypertension subgroup analysis reveal

263 lates positively with vascular remodeling in pulmonary arterial hypertension, suggesting that aldoste

264 rast, HIFs contribute to the pathogenesis of pulmonary arterial hypertension, systemic hypertension a

265 ates of mortality were bridging therapy with pulmonary arterial hypertension-targeted drugs, postoper

266 an attainable goal using the combination of pulmonary arterial hypertension-targeted therapies and L

267 rformed in 35 patients who were treated with pulmonary arterial hypertension-targeted therapies befor

268 In both operated and not-operated patients, pulmonary arterial hypertension-targeted therapy did not

269 ary hypertension, the prognosis is better in pulmonary arterial hypertension than in other Nice categ

270 The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomar

271 imatinib, 2 putative treatments explored for pulmonary arterial hypertension that target aerobic glyc

272 val in patients with idiopathic or heritable pulmonary arterial hypertension to improve risk stratifi

273 randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once

274 domly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, rioc

275 e same patients with idiopathic or heritable pulmonary arterial hypertension, to determine whether th

276 Consecutive patients with idiopathic pulmonary arterial hypertension underwent cardiovascular

277 tured from lungs of patients with idiopathic pulmonary arterial hypertension versus control subjects

278 rtery smooth muscle cells from patients with pulmonary arterial hypertension was reduced by BAY 60-75

279 lly occurring amino acid and a biomarker for pulmonary arterial hypertension was selected as the best

280 Worsening of pulmonary arterial hypertension was the most frequent pr

281 ol subjects and six patients with idiopathic pulmonary arterial hypertension were analyzed.

282 tal, 95 patients with idiopathic or familial pulmonary arterial hypertension were genetically screene

283 A total of 80 patients with idiopathic pulmonary arterial hypertension were identified, and 23

284 ODS AND From 2005 to 2014, 228 patients with pulmonary arterial hypertension were prospectively enrol

285 tudy, in which treatment-naive patients with pulmonary arterial hypertension were randomly assigned i

286 useful for risk stratification in idiopathic pulmonary arterial hypertension, whereas it has not been

287 ation functional class II or III symptoms of pulmonary arterial hypertension who had not previously r

288 Among participants with pulmonary arterial hypertension who had not received pre

289 nown medical history significant for SCD and pulmonary arterial hypertension who was receiving treatm

290 dy population consisted of 605 patients with pulmonary arterial hypertension who were randomly assign

291 cutive patients with idiopathic or heritable pulmonary arterial hypertension with 2 years' follow-up

292 irculating proteins identifies patients with pulmonary arterial hypertension with a high risk of mort

293 nvestigated RV function in patients who have pulmonary arterial hypertension with and without the BMP

294 nilotinib and particularly ponatinib and of pulmonary arterial hypertension with dasatinib have rais

295 In heritable pulmonary arterial hypertension with germline mutation i

296 practical application in progressive/severe pulmonary arterial hypertension with inadequate response

297 We used a transgenic mouse model of pulmonary arterial hypertension with mutant BMPR2 and ge

298 agnetic resonance measurements in idiopathic pulmonary arterial hypertension, with no studies investi

299 udied a family in which multiple members had pulmonary arterial hypertension without identifiable mut

300 ), HF with reduced ejection fraction (n=55), pulmonary arterial hypertension without left heart failu